News & insights

Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia 19 August 2025 Cambridge UK, August 19, 2025 – Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain...

Cognition in The Blood (Biomarker) How do digital cognitive assessments relate to the Blood Plasma p-Tau217 in patients with Mild Cognitive Impairment (MCI)? Our latest research explores an exciting dataset with the AI–Mind Project, who have given us the opportunity to test the associations of our cognitive assessments alongside classic...

Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity 12 August 2025 Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce the commercial launch of a proprietary speaker identification solution developed...

Trading update for period ended 30 June 2025 31st July 2025 Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces a trading update for the six months ended 30 June 2025. Highlights ·    New Sales Orders...

AAIC25 | Posters & Presentations Toronto, Canada | 27th – 31st July | Booth 1531 Unveiling Cutting-Edge Alzheimer’s & Dementia Research at AAIC 2025: A Sneak Peek at Our Latest Posters The Alzheimer’s Association International Conference (AAIC) is just around the corner, and we’re incredibly excited to share some of...